Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap444.85M
Enterprise Value436.15M
CLYM
(NASDAQ)Climb Bio, Inc.
$6.56-- (--)
Loading... - Market loading
Climb Bio (CLYM) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Book (mrq)2.94
Price/Tangible Book (mrq)2.94
Enterprise Value Ratios
EV-based valuation multiples
EV/Earnings-7.29
EV/EBITDA-6.43
EV/EBIT-7.33
EV/FCF-8.00
Stock Price
Current price, 52-week range, and moving averages
Current Price$6.56
1-Day Change1.46%
52-Week High$8.04
52-Week Low$1.05
52-Week Change479.17%
YTD Change85.33%
1-Year Change474.38%
50-Day MA$6.18
200-Day MA$3.22
Avg Volume (30 day)441.10K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding67.81M
Book Value per Share$2.37
Net Cash per Share$0.52
FCF per Share$-0.80
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$16.20
Target Upside/Downside146.95%
Analyst ConsensusStrong Buy
Analyst Count10
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-37.30%
Return on Assets (ttm)-35.68%
Return on Invested Capital (ttm)-37.50%
Return on Capital Employed (ttm)-37.01%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue0.00
Gross Profit-68.00K
Operating Income-67.88M
Pretax Income-59.85M
Net Income-59.85M
EBITDA-67.82M
EBIT-59.50M
Diluted EPS$-0.89
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-54.36M
Capital Expenditures186.00K
Free Cash Flow-54.54M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)167.74M
Cash & Securities (mrq)35.69M
Net Cash (mrq)35.43M
Net Cash per Share$0.52
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)541.00K
Working Capital (mrq)98.86M
Total Equity (mrq)160.47M
Book Value per Share$2.37
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)15.16
Quick Ratio (mrq)15.16
Debt/Equity (mrq)0.00
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-12.70%
FCF Yield-11.57%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score36.02
Piotroski F-Score2/9
Frequently Asked Questions About Climb Bio Statistics
What are the key financial metrics for CLYM?
Climb Bio, Inc. (CLYM) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is CLYM's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Climb Bio is overvalued or undervalued.
How do I read CLYM's profitability ratios?
Climb Bio's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do CLYM's debt ratios indicate?
The financial health section shows Climb Bio's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is CLYM's dividend analysis?
The dividend section covers Climb Bio's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.